Arturo Md Molina Sells 9,514 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 9,514 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total transaction of $784,714.72. Following the completion of the sale, the insider owned 97,266 shares of the company’s stock, valued at approximately $8,022,499.68. This represents a 8.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $84.79 on Friday. The company has a market cap of $5.30 billion, a PE ratio of 136.76 and a beta of 2.26. The firm’s 50 day moving average price is $86.59 and its 200-day moving average price is $71.47. Protagonist Therapeutics, Inc. has a 52-week low of $33.70 and a 52-week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.41 million. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Truist Financial boosted their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Weiss Ratings raised shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. Barclays raised their target price on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.77.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently bought and sold shares of PTGX. Canton Hathaway LLC acquired a new position in Protagonist Therapeutics during the 4th quarter valued at approximately $87,000. Palumbo Wealth Management LLC increased its position in shares of Protagonist Therapeutics by 20.3% in the 4th quarter. Palumbo Wealth Management LLC now owns 6,340 shares of the company’s stock valued at $554,000 after acquiring an additional 1,072 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in Protagonist Therapeutics in the 4th quarter worth $347,000. Exchange Traded Concepts LLC lifted its position in Protagonist Therapeutics by 4.4% during the 4th quarter. Exchange Traded Concepts LLC now owns 35,039 shares of the company’s stock worth $3,060,000 after acquiring an additional 1,487 shares during the period. Finally, GAMMA Investing LLC lifted its position in Protagonist Therapeutics by 62.1% during the 4th quarter. GAMMA Investing LLC now owns 2,672 shares of the company’s stock worth $233,000 after acquiring an additional 1,024 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.